Jeffrey D. Bradley

Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study

Jeffrey D. Bradley, Rebecca Paulus, Ritsuko Komaki et al. · The Lancet Oncology · 2015 · 2K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non–Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial

Stephen G. Chun, Chen Hu, Hak Choy et al. · Journal of Clinical Oncology · 2016 · 748 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non–Small-Cell Lung Cancer

Jeffrey D. Bradley, Chen Hu, Ritsuko Komaki et al. · Journal of Clinical Oncology · 2019 · 578 citations · Full text

Medicine, Oncology, Radiation Oncology +14

Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases

Anthony Mascia, Emily Daugherty, Yongbin Zhang et al. · JAMA Oncology · 2022 · 560 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial

Andrea Bezjak, Rebecca Paulus, Laurie E. Gaspar et al. · Journal of Clinical Oncology · 2019 · 548 citations · Full text

Medicine, Oncology, Radiation Oncology +15